Last updated on March 2017

Macrophages Portal Hypertension and Liver Function During AbbVie Treatment of Chronic Hepatitis C


Brief description of study

Investigation of the effects of the new Abbvie direct acting anti-viral (DAA) treatment of chronic viral hepatitis C infection on the macrophage specific activation marker soluble CD163, portal hypertension determined by the hepatic venous pressure gradient (HVPG), and metabolic liver function determined by the galactose elimination capacity (GEC) test and the functional hepatic nitrogen clearance (FHNC).

Clinical Study Identifier: NCT02526641

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Tea L Laursen, Phd-student

Department of Hepatology and Gastroenterology, Aarhus University Hospital
Aarhus, Denmark
  Connect »